Most of the major players in the medical device arena, and a few from off the bench, are busy touting new products and results from a slew of clinical trials at the European Assn. of Percutaneous Cardiovascular Interventions annual conference, EuroPCR 2010:

Abbott (NYSE:ABT):

Abiomed Inc. (NSDQ:ABMD):

  • Abiomed Reports Updated USpella Results Presented at EuroPCR 2010:

    52% of patients improved New York Heart Association (NYHA) classification by one or more categories after Impella-supported complex PCI. Prior to treatment, 63% of patients were in NYHA class three or four. After treatment, 70% were in NYHA class one or two.

Cordis Corp. [Johnson & Johnson (NYSE:JNJ)]:

InspireMD Ltd.:

Medtronic Inc. (NYSE:MDT):

NMT Medical Inc. (NSDQ:NMTI):

NovoStent Corp.:


St. Jude Medical Inc. (NYSE:STJ):

Tryton Medical Inc.: